Mercado Livre launched prescription medicine sales in São Paulo on 25 September 2026, including GLP-1 drugs and antibiotics, as pharmacy chain shares fell sharply and Abrafarma said it would formally …
Mercado Livre launched prescription medicine sales in São Paulo on 25 September 2026, including GLP-1 drugs and antibiotics, as pharmacy chain shares fell sharply and Abrafarma said it would formally …
The European Commission has approved obicetrapib, as Ubeslo and as Evlarco (with ezetimibe), for adults with primary hypercholesterolaemia or mixed dyslipidaemia — what the companies call a first-in-class approval for …
The FDA approved rebisufligene etisparvovec (Fayuvi) on September 17, 2026 — the first therapy cleared to alter the course of Sanfilippo syndrome type A in pediatric patients, giving Ultragenyx its …
mAbxience and Sandoz have signed a global collaboration agreement to develop and commercialize a biosimilar candidate of emicizumab, targeting the haemophilia A market valued at $5.7 billion.
Argentina’s ANMAT preventively halted all production and sales by Trifarma S.R.L. and Ugal Farmacéutica S.A. and prohibited all their products nationwide, citing technical director and quality control deficiencies.
Brazil’s Health Ministry has formally asked Conitec to evaluate semaglutide and liraglutide for public-system coverage, opening a process that could reshape the country’s obesity-drug market.
Mexico’s Cofepris has granted marketing authorization for lenacapavir as twice-yearly injectable pre-exposure prophylaxis against HIV, placing Mexico among a small group of countries with regulatory access to the long-acting prevention …
The first new-class painkiller in decades has near-universal US coverage and negligible sales — and no clear path to Latin American patients.
Argentina’s Grupo Insud is building a biologics platform: mAbxience exports biosimilars across three continents while Sinergium anchors Latin America’s mRNA vaccine sovereignty.
Same bet, opposite outcomes: Rede D’Or’s insurer-hospital machine compounds while Hapvida’s verticalization buckles under claims, losses and member cuts.
You must be logged in to post a comment.